Oncology, Phase 1 Clinical Trial Centre
Dr. Herbert LOONG
Associate Professor (Clinical)
Department of Clinical Oncology, CUHK
Research Area
- Thoracic oncology
- Sarcoma medical oncology
- Health economics
Professional Profile
Dr. Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Medical Director (Oncology) of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong. Dr. Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a focus on Experimental Therapeutics. He was elected as a Fellow of ASCO (FASCO) in 2024.
Dr. Loong is a recipient of the European Cancer Congress Fellowship Grant (2013), the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.
In recent years, Dr. Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC).
Dr. Loong has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee (IAC) and the Asia-Pacific Regional Council of ASCO. After completing his role as the Chair of the IAC of ASCO (2024-25), he current serves as the Immediate Past Chair (2025-2026). He has also served in the Membership, Education and Communications Committees of the IASLC. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. Dr. Loong is a current Steering Committee member of the Lung Cancer Policy Network (LCPN). In his prior appointment as a member of Pharmacy and Poisons Board of Hong Kong, he oversaw the registration of medicinal products and clinical trials in the territory.